## **Real World Evidence. Meet the Future with Confidence.**

Pharmaceutical Executive



Evidence generation and dissemination in a post-COVID world

IQVIA RWE Virtual Conference | Thursday, June 25, 2020 | 7am EDT - 2pm EDT | 13h CET - 20h CET | No Cost

## **Virtual Conference Agenda**

Additional speakers to be confirmed

CET	EDT	Description
13:00h	7:00am	Welcome, booth time + offering demos
14:30h	8:30am	Keynote Address  Rethinking healthcare post COVID-19: A Human Data Science perspective  Murray Aitken - Executive Director, IQVIA Institute of Human Data Science  The commercial imperative for RWE in launch excellence  Markus Gores, PhD - Vice President Thought Leadership EMEA, IQVIA
15:30h	9:30am	Regulatory progress for COVID-19 treatments and vaccines  Nancy Dreyer, PhD, MPH, FISPE, Fellow DIA - Chief Scientific Officer, IQVIA  Mark McClellan, MD, PhD - Director and Robert J. Margolis MD Professor of Business, Medicine and Policy,  Margolis Center for Health Policy at Duke University
Parallel Sessions Choose one to attend live. All recordings will be available immediately after the conference concludes.		<ul> <li>A) How budget and evidence generation challenges will reshape the European payer and HTA environment Lisa Taylor - Vice President, Head of Europe Consulting, EMEA Commercial and Consulting Services, IQVIA Anke van Engen - Senior Principal, Integrated Value Assessment, IQVIA Jean-François Bergmann, MD - Professor of Internal Medicine, Pharmacology and Therapeutics, University of Paris</li> <li>B) Impact of COVID-19 on provider systems: shifts in healthcare demand, care delivery, and research lan Bonzani - Senior Principal, Real World Networks Team - Healthcare Solutions, IQVIA Moke Sharma - Head of Development Operations &amp; Quantitative Sciences, Alexion Pharmaceuticals Christine Rutan, CPHQ - National Director, Real World Evidence and Health Information Technology, American Heart Association</li> <li>C) How will COVID-19 impact patient willingness to engage with healthcare and research, and what should pharma be thinking about?</li> <li>Stella Karantzoulis, PhD, ABPP-CN - Senior Scientific Advisor, IQVIA Mary New, MBA, DPhil - Senior Principal, Patient Centered Endpoints, IQVIA Konstantina Skaltsa, PhD - Associate Director Statistics, Patient Centered Endpoints, IQVIA</li> </ul>
17:30h	11:30am	How are life science companies preparing for the new normal post COVID-19 and how will RWE, data and technology play a more prominent role?  Andrea Spannheimer - Senior VP, Global Head of Real Word Offerings, Innovations and Partnerships, IQVIA Kathleen Gondek, PhD - Global Head of Evidence and Outcomes, Takeda Ryan D. Kilpatrick, PhD - Head of Global Epidemiology, Pharmacovigilance & Patient Safety, AbbVie Rebecca Meisberger - Director, Real World Evidence, Global Patient Outcomes & Real World Evidence, Eli Lilly and Company Rhys Williams - Vice President of Global Health Economics and Outcomes Research (HEOR), Sunovion
18:30h	12:30pm	Booth time + offering demos
20:00h	2:00pm	Conference close

**CLICK HERE TO BOOK YOUR PLACE** 



